81. De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical Trials.
作者: Yong-Joon Lee.;Xiaofei Gao.;Sang-Hyup Lee.;Jing Kan.;Jun-Jie Zhang.;Seung-Jun Lee.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Byeong-Keuk Kim.;Young-Guk Ko.;Donghoon Choi.;Yangsoo Jang.;Gregg W Stone.;Shao-Liang Chen.;Myeong-Ki Hong.
来源: Ann Intern Med. 2025年178卷4期533-542页
The role of transitioning from short dual antiplatelet therapy (DAPT) to potent P2Y12 inhibitor monotherapy in patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation remains inconclusive.
82. The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful?
作者: Miguel A Hernán.;Issa J Dahabreh.;Barbra A Dickerman.;Sonja A Swanson.
来源: Ann Intern Med. 2025年178卷3期402-407页
When randomized trials are not available to answer a causal question about the comparative effectiveness or safety of interventions, causal inferences are drawn using observational data. A helpful 2-step framework for causal inference from observational data is 1) specifying the protocol of the hypothetical randomized pragmatic trial that would answer the causal question of interest (the target trial), and 2) using the observational data to attempt to emulate that trial. The target trial framework can improve the quality of observational analyses by preventing some common biases. In this article, we discuss the utility and scope of applications of the framework. We clarify that target trial emulation resolves problems related to incorrect design but not those related to data limitations. We also describe some settings in which adopting this approach is advantageous to generate effect estimates that can close the gaps that randomized trials have not filled. In these settings, the target trial framework helps reduce the ambiguity of causal questions.
83. The Effect of Severe Sepsis and Septic Shock Management Bundle (SEP-1) Compliance and Implementation on Mortality Among Patients With Sepsis : A Systematic Review.
作者: James S Ford.;Joseph C Morrison.;May Kyaw.;Meghan Hewlett.;Peggy Tahir.;Sonia Jain.;Shamim Nemati.;Atul Malhotra.;Gabriel Wardi.
来源: Ann Intern Med. 2025年178卷4期543-557页
The Centers for Medicare & Medicaid Services (CMS) Severe Sepsis and Septic Shock Management Bundle (SEP-1) is now included in the Hospital Value-Based Purchasing (VBP) Program.
84. Potential Clinical and Economic Impacts of Cutbacks in the President's Emergency Plan for AIDS Relief Program in South Africa : A Modeling Analysis.
作者: Aditya R Gandhi.;Linda-Gail Bekker.;A David Paltiel.;Emily P Hyle.;Andrea L Ciaranello.;Yogan Pillay.;Kenneth A Freedberg.;Anne M Neilan.
来源: Ann Intern Med. 2025年178卷4期457-467页
Future U.S. congressional funding for the President's Emergency Plan for AIDS Relief (PEPFAR) program is uncertain.
85. Hemochromatosis.
Hemochromatosis is an inheritable condition that mainly affects White populations of European descent. Most patients remain asymptomatic, but others develop advanced organ damage that reduces quality of life and long-term survival. Arthropathy, diabetes mellitus, cirrhosis, hypogonadotropic hypogonadism, and cardiomyopathy are key clinical manifestations. Primary care and hospital medicine physicians play an essential role in early identification of this disease, which can be accomplished via standard hematologic testing. Early diagnosis and therapeutic phlebotomy improve clinical outcomes.
86. Bleeding Risks With Non-Vitamin K Oral Anticoagulants Versus Single Antiplatelet Therapy : A Systematic Review and Meta-analysis of Randomized Trials.
作者: Michael Ke Wang.;Geethan Baskaran.;Ghazal Razeghi.;Richard Ma.;Louis S Park.;Manasi Tannu.;P J Devereaux.;William F McIntyre.;Jeff S Healey.;Ashkan Shoamanesh.;David Conen.
来源: Ann Intern Med. 2025年178卷3期360-368页
In several settings, therapeutic-dose non-vitamin K oral anticoagulants (NOACs) are superior to aspirin for the prevention of arterial and venous thromboembolism.
87. How Would You Manage This Patient With Recent-Onset Atrial Fibrillation? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
作者: Gerald W Smetana.;Eli V Gelfand.;Patricia Tung.;Risa B Burns.
来源: Ann Intern Med. 2025年178卷2期269-278页
Atrial fibrillation (AF) is the most common arrhythmia. Risk factors for AF include obstructive sleep apnea, physical inactivity, obesity, cigarette use, and alcohol misuse. Atrial fibrillation substantially increases the risk for stroke and is associated with higher rates of mortality than for individuals without AF. Strategies to prevent these risk factors and to optimize those that already exist reduce the risk for subsequent AF. Physicians play an important role in proposing strategies to reduce the risk for AF among patients. Decision making regarding management of AF is often complex and requires consideration of symptoms, burden of AF (the percentage of time in AF), comorbid conditions that increase stroke risk, and the risk for bleeding. In particular, novel risk scoring systems to predict stroke risk, and consideration of factors beyond those in these tools, refine the ability to identify patients with AF who are most likely to benefit from anticoagulation to reduce stroke risk. Early use of catheter ablation of AF in selected patients improves symptoms and reduces the potential for progression from intermittent to persistent AF. A 2023 collaborative guideline from the American College of Cardiology, American Heart Association, American College of Chest Physicians, and the Heart Rhythm Society addressed multiple aspects of care of patients with AF. Here, a general cardiologist and a cardiac electrophysiologist discuss recommendations derived from this guideline and how to apply them to the care of a particular patient.
88. Effectiveness and Cost-Effectiveness of Expanded Targeted Testing and Treatment of Latent Tuberculosis Infection Among the Medicare Population in 2022.
作者: Yunfei Li.;Suzanne M Marks.;Garrett R Beeler Asay.;Carla A Winston.;Dawn Pepin.;Susan McClure.;Nicole A Swartwood.;Ted Cohen.;C Robert Horsburgh.;Joshua A Salomon.;Nicolas A Menzies.
来源: Ann Intern Med. 2025年178卷4期479-489页
In the United States, older adults have elevated prevalence of latent tuberculosis infection (LTBI) and incidence of tuberculosis (TB).
89. Assessment and Management of Patients at Risk for Suicide: Synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.
作者: Lisa A Brenner.;Vince Capaldi.;Joseph Constans.;Steven Dobscha.;Matthew Fuller.;Bridget Matarazzo.;Kate McGraw.;Kenneth Richter.;James Sall.;Derek Smolenski.;Scott Williams.;Sarah Davis-Arnold.;Nazanin Bahraini.
来源: Ann Intern Med. 2025年178卷3期416-425页
The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DOD) updated the 2019 joint clinical practice guideline (CPG) for assessing and managing patients who are at risk for suicide. This synopsis provides primary care physicians with a summary of the updated 2024 recommendations regarding evaluation and management of military members and veterans at risk for suicide.
90. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up : A Target Trial Emulation.
作者: George N Ioannou.;Kristin Berry.;Nallakkandi Rajeevan.;Yuli Li.;Lei Yan.;Yuan Huang.;Hung-Mo Lin.;David Bui.;Denise M Hynes.;Mazhgan Rowneki.;Amy Bohnert.;Edward J Boyko.;Theodore J Iwashyna.;Matthew L Maciejewski.;Valerie A Smith.;Theodore S Z Berkowitz.;Ann M O'Hare.;Elizabeth M Viglianti.;Mihaela Aslan.;Kristina L Bajema.
来源: Ann Intern Med. 2025年178卷3期348-359页
Monovalent COVID-19 vaccines targeting the XBB.1.5 Omicron variant were introduced in September 2023. In the absence of randomized controlled trials demonstrating their efficacy, information on real-world vaccine effectiveness (VE) is needed.
91. In acute ischemic stroke with AF, early DOAC initiation was noninferior to delayed initiation for ischemic and hemorrhagic outcomes at 90 d.
GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text] Hematology: [Formula: see text].
92. In arterial hypertension, renal denervation vs. a sham procedure reduces ambulatory and office BP at ≤6 mo.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Nephrology: [Formula: see text].
93. Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians.
作者: Johanna A A Damen.;Bada Yang.;Demy L Idema.;Robin W M Vernooij.;Linde Huis In 't Veld.;Mike Kusters.;Rene Spijker.;Kim van der Braak.;Pauline Heus.;Kevin Jenniskens.;Lotty Hooft.
来源: Ann Intern Med. 2025年178卷3期369-380页
Various treatments for preventing episodic migraine are available.
94. In adults with obesity and knee OA, adding weekly semaglutide to diet and activity counseling reduced weight and knee pain at 68 wk.
GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text] Rheumatology: [Formula: see text].
95. Patients' Values and Preferences Regarding Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review for the American College of Physicians.
作者: Bada Yang.;Robin W M Vernooij.;Demy L Idema.;Linde Huis In 't Veld.;Mike P T Kusters.;Rene Spijker.;Kim van der Braak.;Pauline Heus.;Kevin Jenniskens.;Lotty Hooft.;Johanna A A Damen.
来源: Ann Intern Med. 2025年178卷3期381-388页
Decision making regarding pharmacologic treatments for the prevention of episodic migraine may depend on the importance that patients place on outcomes and specific treatment preferences.
96. Integrated suicide care in primary care improved safety planning and reduced suicide attempts at 90 d.
Mental Health: [Formula: see text] GIM/FP/GP: [Formula: see text] Public Health: [Formula: see text].
97. An intensivist-led telemedicine strategy did not reduce ICU LOS vs. usual care in critically ill patients.
GIM/FP/GP: [Formula: see text] Critical Care: [Formula: see text].
98. In patients with ESUS, the effects of OAC and antiplatelet therapy on recurrent ischemic stroke differ across subgroups at 1 to 5 y.
GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text].
100. In asymptomatic severe AS, early TAVR vs. clinical surveillance reduced a composite of death, stroke, or CV hospitalization.
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
|